Yasmin Abaza

Hematology | Oncology
675 N St Clair St Ste 21-100
Galter Pavilion
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2026

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Journal: American journal of hematology
Published: June 25, 2026

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

Journal: Leukemia
Published: May 05, 2026

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Journal: Blood cancer journal
Published: March 13, 2026

Myeloid neoplasms with mutated KIT: comparative clinicopathologic analysis of D816 vs. non-D816 variants.

Myeloid neoplasms with mutated KIT: comparative clinicopathologic analysis of D816 vs. non-D816 variants.

Journal: Cancer genetics
Published: January 24, 2026

Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.

Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.

Journal: Leukemia & lymphoma
Published: December 23, 2025

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

Journal: British journal of haematology
Published: December 08, 2025

Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?

Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?

Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.

Journal: Blood advances
Published: October 27, 2025

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Journal: Blood cancer journal
Published: October 05, 2025

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Journal: Blood advances
Published: August 22, 2025
Showing 1-12 of 62

Last Updated: 09/26/2026